These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 6382892)

  • 21. A study of serum free C-peptide responses to oral glucose load in diabetic patients: with special reference to types of diabetes and methods of treatment.
    Hsieh SD; Akanuma Y; Takaku F
    Tohoku J Exp Med; 1984 Mar; 142(3):249-60. PubMed ID: 6374968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy.
    Hosker JP; Rudenski AS; Burnett MA; Matthews DR; Turner RC
    Metabolism; 1989 Aug; 38(8):767-72. PubMed ID: 2668699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of strict blood glucose control on residual B-cell function in insulin-dependent diabetics.
    Madsbad S; Krarup T; Reguer L; Faber OK; Binder C
    Diabetologia; 1981 May; 20(5):530-4. PubMed ID: 7026327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Residual B cell function in patients with long-standing NIDDM and its relation to metabolic control and diabetic complications.
    Iwase M; Kikuchi M; Nunoi K; Maki Y; Wakisaka M; Wada M; Fujishima M
    Endocrinol Jpn; 1988 Dec; 35(6):803-8. PubMed ID: 3074917
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
    Østoft SH
    Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. beta-cell function in children with diabetes.
    Ludvigsson J; Heding LG
    Diabetes; 1978; 27 Suppl 1():230-4. PubMed ID: 344114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impaired insulin secretion and increased insulin sensitivity in familial maturity-onset diabetes of the young 4 (insulin promoter factor 1 gene).
    Clocquet AR; Egan JM; Stoffers DA; Muller DC; Wideman L; Chin GA; Clarke WL; Hanks JB; Habener JF; Elahi D
    Diabetes; 2000 Nov; 49(11):1856-64. PubMed ID: 11078452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beta cell function in long term NIDDM (type 2) patients and its relation to treatment.
    Snehalatha C; Ramachandran A; Mohan V; Timothy H; Viswanathan M
    Horm Metab Res; 1986 Jun; 18(6):391-4. PubMed ID: 3525362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fasting plus prandial insulin supplements improve insulin secretory ability in NIDDM subjects.
    Kawamori R; Bando K; Yamasaki Y; Kubota M; Watarai T; Iwama N; Shichiri M; Kamada T
    Diabetes Care; 1989; 12(10):680-5. PubMed ID: 2515048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of exogenous insulin on C-peptide levels in subjects with type 2 diabetes.
    Albareda M; Rigla M; Rodríguez-Espinosa J; Caballero A; Chico A; Cabezas R; Carreras G; Pérez A
    Diabetes Res Clin Pract; 2005 Jun; 68(3):202-6. PubMed ID: 15936461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of the combination of insulin and gliclazide compared with insulin alone in type 2 diabetic patients with secondary failure to oral hypoglycemic agents.
    Aschner P; Kattah W
    Diabetes Res Clin Pract; 1992 Oct; 18(1):23-30. PubMed ID: 1446575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. betacell function during insulin or chlorpropamide treatment of maturity-onset diabetes mellitus.
    Turner RC; Holman RR
    Diabetes; 1978; 27 Suppl 1():241-6. PubMed ID: 344115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma C-peptide levels identify insulin-treated diabetic patients suitable for oral hypoglycaemic therapy.
    Grant PJ; Barlow E; Miles DW
    Diabet Med; 1984 Nov; 1(4):284-6. PubMed ID: 6242818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variation of endogenous insulin secretion in association with treatment status: assessment by serum C-peptide and modified urinary C-peptide.
    Aoki Y
    Diabetes Res Clin Pract; 1991 Dec; 14(3):165-73. PubMed ID: 1778109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Secretory B-cell activity in insulin dependent maturity-onset diabetic.
    Krause U; Faisst G; Cordes U; Beyer J
    Horm Metab Res; 1979 Apr; 11(4):261-5. PubMed ID: 378805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Studies on urinary C-peptide excretion in normal children and children with insulin-dependent diabetes mellitus].
    Kusayanagi T
    Nihon Ika Daigaku Zasshi; 1989 Apr; 56(2):103-22. PubMed ID: 2659621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study.
    Levy J; Atkinson AB; Bell PM; McCance DR; Hadden DR
    Diabet Med; 1998 Apr; 15(4):290-6. PubMed ID: 9585393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Control of non-insulin dependent diabetes is not correlated with endogenous insulin secretion.
    Lev-Ran A; Hwang D; Barseghian G; Hill LR
    Diabete Metab; 1986 Dec; 12(6):325-8. PubMed ID: 3545932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application.
    Rosak C; Hofmann U; Paulwitz O
    Diabetes Nutr Metab; 2004 Jun; 17(3):137-42. PubMed ID: 15334790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucagon-stimulated insulin secretion in patients with type 2 diabetes mellitus: support for the concept of glucose toxicity.
    Wolffenbuttel BH; Menheere PP; Nijst L; Rondas-Colbers GJ; Sels JP; Nieuwenhuijzen Kruseman AC
    Neth J Med; 1992 Jun; 40(5-6):277-82. PubMed ID: 1436266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.